Newark, CA (Press Release) – Teneobio, Inc. a clin­i­cal-stage bio­technology com­pany devel­op­ing engi­neered bispecific anti­bodies for the treat­ment of cancer announced today that the first patient has been dosed with TNB-383B in a Phase 1 clin­i­cal study to eval­u­ate the safety and tolerability of its dif­fer­en­ti­ated anti-BCMAxCD3, a bispecific anti­body that redirects T-cells to kill multiple myeloma cells with minimal cytokine release. Earlier this year, Teneobio’s affiliate TeneoOne, Inc. and AbbVie entered a strategic part­ner­ship, giving AbbVie the exclusive right to acquire TeneoOne post-Phase 1 studies and lead the sub­se­quent global devel­op­ment and com­mer­cial­iza­tion of TNB-383B.

“Redirecting T-cells to kill cancer cells is a powerful thera­peutic ap­proach in the immuno-oncology space. We designed TNB-383B to efficiently kill multiple myeloma cells expressing BCMA and minimize cytokine release from CD3-activated T-cells. This latter attribute is a hallmark of our unique T-cell CD3 engaging thera­peutic plat­form, which is in a number of our follow-on pro­grams and lead clin­i­cal can­di­dates,” said Roland Buelow, CEO at Teneobio. “Our new class of T-cell engagers were designed to in­crease the thera­peutic window as monotherapies and they may also afford the oppor­tu­ni­ty for com­bi­na­tion treat­ments of patients.”

The TNB-383B Phase 1 study involves a dose-escalation study that will char­ac­ter­ize the safety and tolerability, phar­ma­co­ki­netics, pharmacodynamics, immunogenicity and pre­lim­i­nary anti-cancer activity of in­tra­venous admin­istra­tion of TNB-383B in patients with re­lapsed or refractory multiple myeloma. For more in­for­ma­tion about the trial please visit https://clinicaltrials.gov (identifier: NCT03933735).

About Teneobio, Inc.

Teneobio, Inc. is a clin­i­cal stage bio­technology com­pany devel­op­ing a new class of biologics, Human Heavy-Chain Antibodies (UniAbs™), for the treat­ments of cancer, autoimmunity, and infectious diseases. Teneobio’s discovery plat­form, TeneoSeek, com­prises genetically engi­neered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly tech­nolo­gies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for thera­peutic targets of interest. Versatile anti­body variable domains (UniDabs™) derived from UniAbs™ can be assembled into multi-specific and multivalent thera­peutic proteins, surpassing limitations of con­ven­tional anti­body thera­peutics. Teneobio’s “plug-and-play” T-cell engaging plat­form in­cludes a diverse set of anti-CD3 anti­bodies for thera­peutics with optimal efficacy and reduced toxicity. The com­pany has received funding from institutional in­vestors, in­clud­ing Lightspeed Venture Partners and Sutter Hill Ventures. For more in­for­ma­tion, visit www.teneobio.com.

Source: Teneobio.